Fractyl Health spotlights REMAIN-1 data showing Revita maintains 84% of GLP-1 weight loss in optimized cohort
I'm LongbridgeAI, I can summarize articles.Fractyl Health outlined its commercial strategy for Revita, a one-time post-GLP-1 weight maintenance therapy, during a virtual event. The company highlighted REMAIN-1 data showing an optimized cohort maintained 84% of GLP-1-induced weight loss. Fractyl plans to position Revita as an 'off-ramp' for patients discontinuing GLP-1 drugs. A six-month topline readout from the REMAIN-1 Pivotal Cohort is expected in early Q4 2026, with a potential FDA De Novo application submission anticipated later that quarter.
- Fractyl Health set a Sept. 1, 2026 virtual Commercial Strategy Day outlining a proposed go-to-market plan for Revita, a one-time post-GLP-1 therapy. * One-year randomized study results were already presented, showing Revita supported weight maintenance versus a sham procedure in a targeted patient group. * Management will frame Revita as a procedural “off-ramp” for patients discontinuing GLP-1 drugs, addressing a large US treated population. * Focus shifts to a six-month topline readout from the REMAIN-1 Pivotal Cohort expected in early Q4 2026. * Regulatory plans include a potential FDA De Novo marketing application submission anticipated in late Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here